Low skeletal muscle density as predictive for febrile neutropenia in patients treated by doxorubicin/trabcctedin/pegfilgrastim combination as a first line treatment of advanced or metastatic leiomyosarcoma (LMS) (LMS02 study).

被引：0

作者：

Antoun, Sami

Floquet, Anne

Penel, Nicolas

Delcambre, Corinne

Chevreau, Christine

Cupissoi, Didier

Alexandre, Jerome

Duffaud, Florence

Lacas, Benjamin

Pautier, Patricia

机构：

[1] Gustave Roussy, Villejuif, France

[2] Inst Bergonie, Bordeaux, France

[3] Ctr Oscar Lambret, F-59020 Lille, France

[4] Ctr Francois Baclesse, F-14021 Caen, France

[5] Inst Claudius Regaud, Toulouse, France

[6] Ctr Val dAurelle Paul Lamarque, Dept Med Oncol, Montpellier, France

[7] Paris Descartes Univ, Cochin Hosp, AP HP, Sorbonne Paris Cite, Paris, France

[8] La Timone Univ Hosp, Marseille, France

[9] Gustave Roussy, Dept Med, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.e20640

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20640

引用

页数：1

共 10 条

[1] LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.
Pautier, Patricia
Floquet, Anne
Cupissol, Didier
Lacas, Benjamin
Bompas, Emmanuelle
Chevreau, Christine
Selle, Frederic
Weber, Beatrice E.
Guillemet, Cecile
Penel, Nicolas
Duffaud, Florence
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.
Pautier, Patricia
Floquet, Anne
Chevreau, Christine
Penel, Nicolas
Guillemet, Cecile
Delcambre, Corinne
Cupissol, Didier
Selle, Frederic
Isambert, Nicolas
Piperno-Neumann, Sophie
Saada-Bouzid, Esma
Bertucci, Francois
Bompas, Emmanuelle
Boudou-Rouquette, Pascaline
Collard, Olivier
Ly, Valerie Le Brun
Toulmonde, Maud
Le Cesne, Axel
Lacas, Benjamin
Duffaud, Florence
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS).
Bitz, U.
Pink, D.
Busemann, C.
Reichardt, P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[4] Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
Pautier, Patricia
Floquet, Anne
Chevreau, Christine
Penel, Nicolas
Guillemet, Cecile
Delcambre, Corinne
Cupissol, Didier
Selle, Frederic
Isambert, Nicolas
Piperno-Neumann, Sophie
Thyss, Antoine
Bertucci, Francois
Bompas, Emmanuelle
Alexandre, Jerome
Collard, Olivier
Lavau-Denes, Sandrine
Soulie, Patrick
Toulmonde, Maud
Le Cesne, Axel
Lacas, Benjamin
Duffaud, Florence
[J]. LANCET ONCOLOGY, 2015, 16 (04): : 457 - 464
[5] LMS-02: A Phase II single-arm multicenter study to determine the efficacy of doxorubicin in combination with trabectedin as a 1st line treatment of metastatic and/or locally advanced leiomyosarcoma of uterine (U-LMS) or soft tissue (ST-LMS) origin: results of the soft tissue group
Pautier, P.
Chevreau, C.
Le Cesne, A.
Penel, N.
Bui, B.
Guillemet, C.
Delcambre, C.
Rey, A.
Duffaud, F.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S887 - S887
[6] Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
D'Ambrosio, Lorenzo
Touati, Nathan
Blay, Jean-Yves
Grignani, Giovanni
Flippot, Ronan
Czarnecka, Anna Malgorzata
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma
Cote, Gregory Michael
Chawla, Sant P.
Demetri, George
Kasper, Bernd
Jones, Robin Lewis
Broto, Javier Martin
Wooley, Joseph
Weiss, Mia C.
Tafuto, Salvatore
Badalamenti, Giuseppe
Carrasco-Garcia, Irene
Peinado, Paloma
Blay, Jean-Yves
Boggio, Gaston
Fernandez, Cristian Marcelo
Nieto, Antonio
Kahatt, Carmen Maria
Zeaiter, Ali Hassan
Le Cesne, Axel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
Pautier, P.
Italiano, A.
Piperno-Neumann, S.
Chevreau, C. M.
Penel, N.
Cupissol, D.
Rouquette, P. Boudou
Bertucci, F.
Balleyguier, C.
Lebrun-Ly, V.
Blay, J-Y.
Kalbacher, E.
Delcambre, C.
Bompas, E.
Collard, O.
Isambert, N.
Guillemet, C.
Rios, M.
Sundqvist, M.
Duffaud, F.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1335 - S1336
[9] Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer
Amadori, D.
Gasparini, G.
Ardizzoni, A.
Comella, G.
Saracchini, S.
Barone, C.
Bordonaro, R.
Djazouli, K.
Barbalo, A.
[J]. CANCER RESEARCH, 2009, 69 (02) : 247S - 247S
[10] Pegfilgrastim reduces the incidence of neutropenia in patients with locally advanced or metastatic colon cancer receiving chemotherapy administered every 2 weeks as first- or second-line treatment: A phase 2, double-blind, placebo-controlled study
Hecht, J.
Malik, I
Gollard, R.
Patel, R.
Tomita, D.
Dreiling, L.
[J]. ANNALS OF ONCOLOGY, 2007, 18 : VII31 - VII31

← 1 →